Cancer-id

Toward identification of cancer by tumor-derived extracellular vesicles in blood

Journal article (2020)

Authors

L. G. Rikkert Amsterdam UMC, University of Twente
P. Beekman Wageningen University & Research, University of Twente
J. Caro ImPhys/Computational Imaging - AS
F. A.W. Coumans Amsterdam UMC
A. Enciso-Martinez University of Twente
G Jenster Erasmus MC
S. Le Gac University of Twente
W. Lee University of Twente
G.B. Loozen ImPhys/Computational Imaging - AS
More Authors... External organisation
Research Group
ImPhys/Computational Imaging (AS) (TU Delft)
Copyright: © 2020 L. G. Rikkert, P. Beekman, J. Caro-Schuurman, F. A.W. Coumans, A. Enciso-Martinez, G. Jenster, S. Le Gac, W. Lee, G.B. Loozen, More Authors
DOI: https://doi.org/10.3389/fonc.2020.00608
More Info
expand_more

Published Date

2020

Language

English

Faculty

Applied Sciences

Department

ImPhys/Imaging Physics

Research Group

ImPhys/Computational Imaging

Abstract

Extracellular vesicles (EVs) have great potential as biomarkers since their composition and concentration in biofluids are disease state dependent and their cargo can contain disease-related information. Large tumor-derived EVs (tdEVs, >1μm) in blood from cancer patients are associated with poor outcome, and changes in their number can be used to monitor therapy effectiveness. Whereas, small tumor-derived EVs (<1μm) are likely to outnumber their larger counterparts, thereby offering better statistical significance, identification and quantification of small tdEVs are more challenging. In the blood of cancer patients, a subpopulation of EVs originate from tumor cells, but these EVs are outnumbered by non-EV particles and EVs from other origin. In the Dutch NWO Perspectief Cancer-ID program, we developed and evaluated detection and characterization techniques to distinguish EVs from non-EV particles and other EVs. Despite low signal amplitudes, we identified characteristics of these small tdEVs that may enable the enumeration of small tdEVs and extract relevant information. The insights obtained from Cancer-ID can help to explore the full potential of tdEVs in the clinic.